Kadmon Holdings Llc (KDMN)
$3.53 0.00 (0.00%)
19:25 EDT KDMN Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 278.15M
PE Ratio -2.72
Volume (Avg. Vol.)
Day's Range 3.53 - 3.53
52-Week Range 2.30 - 5.50
Dividend & Yield N/A (N/A)
KDMN Stock Predictions, Articles, and Kadmon Holdings Llc News
- From InvestorPlace
- From the Web
As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.
In times of market turbulence, cheap stocks offer a unique way to escape the broad moves up and down and instead benefit from big potential.
Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.
These biotech stocks are set for a strong comeback as investors start to walk away from large-cap tech companies. Here's what investors need to know about each company.
From Smarter Analyst
NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020. "With the acceptance of Kadmon's new drug application for belumosudil in cGVHD in hand, we are preparing for our potential commercial launch in light of our May 30th PDUFA date," said Harlan W. Waksal, M.D.,
NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance
From Market News Video
NEW YORK, NY / ACCESSWIRE / February 24, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present and host investor meetings at the following virtual investor conferences: Raymond James 42nd Annual Institutional Investors Conference - Date: Wednesday, March 3, 2021 - Time: 4:40pm ET H.C. Wainwright Global Life Sciences Conference -
Kadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Million Over-Allotment Option
NEW YORK, NY / ACCESSWIRE / February 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the closing of $240 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private, overnight offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, which includes the full exercise of the $40 million over-allotment option. The initial
Navellier RatingsPowered by Portfolio Grader